DrugPatentWatch Database Preview
Details for Patent: 10,213,512
» See Plans and Pricing
Which drugs does patent 10,213,512 protect, and when does it expire?
Patent 10,213,512 protects AMZEEQ and ZILXI and is included in two NDAs.
This patent has twenty-seven patent family members in ten countries.
Summary for Patent: 10,213,512
| Title: | Topical tetracycline compositions |
| Abstract: | A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force. |
| Inventor(s): | Tamarkin; Dov (Maccabim, IL), Gazal; Elana (Rehovot, IL), Papiashvili; Irakliy (Ashkelon, IL), Hazot; Yohan (Rehovot, IL), Schuz; David (Gimzu, IL), Keynan; Rita (Rehovot, IL) |
| Assignee: | FOAMIX PHARMACEUTICALS LTD. (Rehovot, IL) |
| Application Number: | 15/591,733 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,213,512
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foamix | AMZEEQ | minocycline hydrochloride | AEROSOL, FOAM;TOPICAL | 212379-001 | Oct 18, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | TREATMENT OF NON-NODULAR ACNE VULGARIS | Start Trial | |||
| Foamix | ZILXI | minocycline hydrochloride | AEROSOL, FOAM;TOPICAL | 213690-001 | May 28, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,213,512
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2010302350 | Start Trial | |||
| Australia | 2015224534 | Start Trial | |||
| Brazil | 112012007473 | Start Trial | |||
| Canada | 2776366 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
